Other drug therapy

Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 19, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Recurrent Mycosis Fungoides and Sézary Syndrome / Treatment Options for Recurrent Mycosis Fungoides and Sézary Syndrome

Symptomatic management with topical corticosteroids.

Bexarotene, an oral or topical retinoid.[33,34]

Source links and citations

Lenalidomide.[35]

Source links and citations

Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[36-38]

Source links and citations

Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[36-38]

A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; P = .01).[26][Level of evidence C3]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice